Please login to the form below

Not currently logged in
Email:
Password:

Lilly forms hypoglycaemia drug pact

Eli Lilly has acquired worldwide commercialisation rights to a developmental hypoglycaemia therapy from Marcadia Biotech

Eli Lilly has acquired worldwide commercialisation rights to a glucagon analogue under development for severe hypoglycaemia in people with diabetes from Marcadia Biotech. Marcadia is an Indiana-based company founded five years ago to focus on developing drugs for diabetes and obesity using proprietary peptide chemistry.

The companies hope that the hypoglycaemia therapy, which is currently in preclinical development, will provide an alternative to currently marketed glucagon products, which need to be refrigerated and also must be reconstituted from a powder before they can be injected. Lilly and Marcadia aim to develop this new product as a premixed solution in a convenient single-use auto-injection "pen" device that can be stored at room temperature.

The agreement between the two companies covers the glucagon analogue MAR531 and also a stable of related back-up compounds. The deal calls for Marcadia to continue to oversee development of the product through US approval, but gives Lilly responsibility for regulatory approval in countries outside the US and for commercialisation worldwide.

MAR531 and the related compounds were discovered through Marcadia's sponsored research agreement with Indiana University, Bloomington. Financial terms of the deal with Lilly were not disclosed.

Lilly is already a leader in the diabetes space, with a portfolio that includes the type II diabetes drug Byetta (exenatide).

29th June 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...
InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...

Infographics